Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

By Robin Sawka, BioCentury Staff, BioCentury Staff | Mar 12, 2020 | 12:41 AM GMT
Editor's note: Updated on Mar 12, 2020 at 1:00 AM GMT

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming CEO in 2018.

Antibody-based cancer therapy company Genmab A/S (CSE:GMAB; NASDAQ:GMAB) hired Anthony Mancini as EVP and COO, effective March 23. He

Read the full 572 word article

How to gain access

Continue reading with a
two-week free trial.